Keytruda, Avastin, Lixiana get reimbursement in Scotland; Exchange plans limit access to HIV meds;

@FiercePharma: #ICYMI yesterday: U.S. judge orders Valeant, Ackman to face insider trading suit. Story | Follow @FiercePharma

@EricPFierce: ICYMI: #Novo makes sure Denmark gets some of the action as it starts massive build up. More | Follow @EricPFierce

@CarlyHFierce: U.S. judge orders Valeant, Ackman to face insider trading suit. Article | Follow @CarlyHFierce

> The Scottish Medicines Consortium gave its thumbs up to Merck & Co.'s ($MRK) cancer immunotherapy Keytruda in melanoma, Roche's ($RHHBY) Avastin for ovarian cancer, and Daiichi Sankyo's blood thinner Lixiana. Report

> The Trans-Pacific Partnership could limit the availability of affordable medicines, World Health Organization chief Margaret Chan said Thursday. Report

> Despite long-standing recommendations to screen patients using antipsychotics for diabetes annually, only 30% receive the tests, a study found. Report

> Some Affordable Care Act exchange plans have limited the number of HIV drugs covered or charge higher out-of-pocket costs for them, a new analysis found. Report

> Chinese regulators stiff-armed 11 new drug applications because of inadequate data in a quality-oriented crackdown. Report

Medical Device News

@FierceMedDev: AliveCor adds former Google exec as CEO to further consumer ECG push. Story | Follow @FierceMedDev

@VarunSaxena2: Boston Sci's Watchman hit by restrictive CMS coverage decision, recall over blood leakage. Article | Follow @VarunSaxena2

@EmilyWFierce: Women are suing Endo Health Solutions and Patheon for child support after contraceptive packaging mishap. More | Follow @EmilyWFierce

> Resurgent 23andMe CEO says the genetic testing company is not up for sale. Article

> Philips to launch pneumonia Dx wearable to prevent child deaths in poorer countries. News

Biotech News

@FierceBiotech: China's new pharma crackdown may help top companies. Story | Follow @FierceBiotech

@JohnCFierce: Gilead, Sanofi singled out as worst offenders in failing to disclose trial data. More | Follow @JohnCFierce

@DamianFierce: $HZNP "is threatening $ESRX's profiteering and exposing ... a lack of care for patients and respect for physicians." News | Follow @DamianFierce

> Biogen's risky Alzheimer's odyssey raises prospects for new biotech deals. Story

> Portola rolls toward approval for its 'breakthrough' anticoagulant antidote. More

CRO News

> Quintiles lends its data-crunching know-how to Apple's ResearchKit. More

> PPD deepens its Japanese focus with new joint venture leadership. Story

> WuXi and Lilly pair up to develop a cardio drug in China. Article

> CRO BioDuro merges with Formex after a private equity takeout. More

> Quintiles founder stepping down as chairman after 33 years. News

Pharma Manufacturing News

> Endo, Patheon sued over unplanned pregnancies tied to contraceptive mishap. Item

> CMO Formex and CRO BioDuro merge operations. More

> Cellular Biomedicine adds facility in China that will help with CAR-T processing. Story

> AmerisourceBergen says quality will be PharMEDium's distinguisher, but acknowledges 'quick diligence' ahead of deal. Report

> Pharma cargo thefts jump with $558,000 average losses reported. News

Pharma Asia News

> India's drug regulator handcuffed by low funding, lack of trained personnel. Story

> Japan's Astellas Pharma gets $727M for ailing dermatology unit as it swings to new areas. More

> WuXi and Eli Lilly in pact on cardio candidate development in China. Article

> Japanese ministry knocks Novartis unit, again, on side effects nondisclosure. News

> Daiichi loses Supreme Court decision on Apotex generic. More

And Finally... Pfizer's ($PFE) vitamin C supplement Emergen-C was among a list of supplement brands called out by CBC for failing to live up to their labels. Report

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.